BioClin Therapeutics inks $30 mln Series B
San Ramon, California-based drug developer BioClin Therapeutics Inc has secured $30 million in Series B financing. Sofinnova Ventures and Ysios Capital led the round with participation from other investors that included HealthCap, Life Sciences Partners and Tekla Capital Management.
22 March 2017•1 min read
